Trilogy International Partners Inc, together with its subsidiaries, provides wireless voice and data communication services in Bolivia and New Zealand. The company's communications services include local, international long distance, and roaming services for customers and international visitors roaming on their networks. It also provides fixed broadband communications services to business and residential customers.
Read More…
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-425-4585900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$764.72 million
Profitability
Miscellaneous
Employees1,821
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable
Trilogy International Partners (TSE:TRL) Frequently Asked Questions
What is Trilogy International Partners' stock symbol?
Trilogy International Partners trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRL."
How often does Trilogy International Partners pay dividends? What is the dividend yield for Trilogy International Partners?
Trilogy International Partners announced an annual dividend on Monday, April 15th. Shareholders of record on Monday, May 6th will be paid a dividend of 0.02 per share on Monday, May 6th. This represents a yield of 0.86%. The ex-dividend date of this dividend is Monday, April 15th. View Trilogy International Partners' Dividend History.
When is Trilogy International Partners' next earnings date?
What price target have analysts set for TRL?
2 equities research analysts have issued 1-year price objectives for Trilogy International Partners' stock. Their predictions range from C$3.50 to C$3.50. On average, they anticipate Trilogy International Partners' stock price to reach C$3.50 in the next year. This suggests a possible upside of 44.0% from the stock's current price. View Analyst Price Targets for Trilogy International Partners.
What is the consensus analysts' recommendation for Trilogy International Partners?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trilogy International Partners in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trilogy International Partners.
Has Trilogy International Partners been receiving favorable news coverage?
News headlines about TRL stock have been trending positive on Sunday, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Trilogy International Partners earned a coverage optimism score of 2.5 on InfoTrie's scale. They also gave media stories about the specialty pharmaceutical company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the near future. View News Stories for Trilogy International Partners.
Who are some of Trilogy International Partners' key competitors?
Some companies that are related to Trilogy International Partners include Vectura Group (VEC), Medical Developments International (MVP), Eco Animal Health Group (EAH), BEXIMCO PHARMAC/S GDR REGS (BXP), Futura Medical (FUM), Pharmaxis (PXS), Allergy Therapeutics (AGY), Vita Life Sciences (VLS), Patrys (PAB), Recce Pharmaceuticals (RCE), Avivagen (VIV), Antisense Therapeutics (ANP), Cathay International (CTI), NanoViricides (NNVC) and China Pharma (CPHI).
What other stocks do shareholders of Trilogy International Partners own?
Who are Trilogy International Partners' key executives?
Trilogy International Partners' management team includes the folowing people:
- Mr. John William Stanton, Chairman (Age 64)
- Mr. Bradley Jay Horwitz, Co-Founder, Pres, CEO & Non-Independent Director (Age 63)
- Ms. Theresa E. Gillespie, Co-Founder & Non-Independent Director (Age 66)
- Mr. Erik Mickels, Sr. VP & CFO
- Mr. Scott Morris, Sr. VP, Gen. Counsel & Corp. Sec.
How do I buy shares of Trilogy International Partners?
Shares of TRL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Trilogy International Partners' stock price today?
One share of TRL stock can currently be purchased for approximately C$2.43.
How big of a company is Trilogy International Partners?
What is Trilogy International Partners' official website?
How can I contact Trilogy International Partners?
Trilogy International Partners' mailing address is Bellevue Wa PO Box 1988, BELLEVUE, WA 98009-1988, United States. The specialty pharmaceutical company can be reached via phone at +1-425-4585900.
MarketBeat Community Rating for Trilogy International Partners (TSE TRL)
MarketBeat's community ratings are surveys of what our community members think about Trilogy International Partners and other stocks. Vote "Outperform" if you believe TRL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRL will underperform the S&P 500 over the long term. You may vote once every thirty days.
